208 related articles for article (PubMed ID: 20157707)
1. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
Cordier D; Forrer F; Bruchertseifer F; Morgenstern A; Apostolidis C; Good S; Müller-Brand J; Mäcke H; Reubi JC; Merlo A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1335-44. PubMed ID: 20157707
[TBL] [Abstract][Full Text] [Related]
2. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S; Cordier D; Good S; Ionescu MC; Ghaffari A; Hofer S; Kretzschmar M; Tolnay M; Apostolidis C; Waser B; Arnold M; Mueller-Brand J; Maecke HR; Reubi JC; Merlo A
Clin Cancer Res; 2006 Jun; 12(12):3843-50. PubMed ID: 16778112
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Results of Targeted Low-Grade Glioma Treatment with
Cordier D; Merlo A
Cancer Biother Radiopharm; 2019 Aug; 34(6):413-416. PubMed ID: 30844298
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of targeted alpha therapy with
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with
Krolicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1636-1644. PubMed ID: 29713762
[TBL] [Abstract][Full Text] [Related]
7. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters.
Królicki L; Kunikowska J; Bruchertseifer F; Kuliński R; Pawlak D; Koziara H; Rola R; Morgenstern A; Merlo A
Clin Nucl Med; 2023 May; 48(5):387-392. PubMed ID: 36854309
[TBL] [Abstract][Full Text] [Related]
9. Targeted Radiolabeled Compounds in Glioma Therapy.
Cordier D; Krolicki L; Morgenstern A; Merlo A
Semin Nucl Med; 2016 May; 46(3):243-9. PubMed ID: 27067505
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
11. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
[TBL] [Abstract][Full Text] [Related]
12.
Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
[TBL] [Abstract][Full Text] [Related]
13. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
Kneifel S; Bernhardt P; Uusijärvi H; Good S; Plasswilm L; Buitrago-Téllez C; Müller-Brand J; Mäcke H; Merlo A
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1388-95. PubMed ID: 17265035
[TBL] [Abstract][Full Text] [Related]
14. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
17. Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi
Suthiram J; Ebenhan T; Marjanovic-Painter B; Sathekge MM; Zeevaart JR
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575402
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
19. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
[TBL] [Abstract][Full Text] [Related]
20. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
